Fate Therapeutics, Inc.(FATE)

$2.45—Earnings · Aug 11

Chart

Fate Therapeutics, Inc.(FATE)

NASDAQ

$2.45—Earnings · Aug 11

Chart Studio

FATE(FATE)

FATE

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.28

Aug 11, 2026 · Reports before open

Revenue Estimate

$1M

Analyst Sentiment

Wall St. Consensus

Hold

30 analysts·High coverage

Score

16 Buy (53%)12 Hold (40%)2 Sell (7%)

Rating Breakdown

Strong Buy

00%

Buy

1653%

Hold

1240%

Sell

27%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$4.00

+63.3%

Consensus

$5.50

+124.5%

Bull

$7.00

+185.7%

12-Month Target Range30 analysts

$4.00$5.50$7.00

Current $2.45Consensus

Current Price

$2.45

Upside to Consensus

$3.05

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-0.68%

EPS—

FY2028

Rev-2.47%

EPS—

FY2029

Rev+1076.14%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$5M	$5M	$5M	$60M	$156M
Low	$1M	$2M	$2M	$24M	$62M
High	$14M	$12M	$11M	$132M	$345M
EBITDA Avg	$-5M	$-5M	$-5M	$-60M	$-156M
Low	$-14M	$-12M	$-11M	$-132M	$-345M
High	$-1M	$-2M	$-2M	$-24M	$-62M
EBIT Avg	$-5M	$-5M	$-5M	$-60M	$-156M
Low	$-14M	$-12M	$-11M	$-132M	$-345M
High	$-1M	$-2M	$-2M	$-24M	$-62M
Net Income Avg	$-135M	$-155M	$-165M	$-118M	$-80M
Low	$-150M	$-169M	$-194M	$-302M	$-204M
High	$-77M	$-40M	$-71M	$-26M	$-17M
EPS Avg	$-1.08	$-1.03	$-1.07	$-0.99	$-0.67
Low	$-1.26	$-1.43	$-1.63	$-2.54	$-1.72
High	$-0.64	$-0.33	$-0.60	$-0.21	$-0.15
Analysts (Rev / EPS)	9 / 9	7 / 8	6 / 5	5 / 1	3 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$1M	$1M	$999,875	$999,875	$987,375	$987,375	$773,301	$724,754
Low	$1M	$1M	$999,875	$999,875	$987,375	$987,375	$773,301	$724,754
High	$1M	$1M	$999,875	$999,875	$987,375	$987,375	$773,301	$724,754
EBITDA Avg	$-1M	$-1M	$-999,875	$-999,875	$-987,375	$-987,375	$-773,301	$-724,754
Low	$-1M	$-1M	$-999,875	$-999,875	$-987,375	$-987,375	$-773,301	$-724,754
High	$-1M	$-1M	$-999,875	$-999,875	$-987,375	$-987,375	$-773,301	$-724,754
EBIT Avg	$-1M	$-1M	$-999,875	$-999,875	$-987,375	$-987,375	$-773,301	$-724,754
Low	$-1M	$-1M	$-999,875	$-999,875	$-987,375	$-987,375	$-773,301	$-724,754
High	$-1M	$-1M	$-999,875	$-999,875	$-987,375	$-987,375	$-773,301	$-724,754
Net Income Avg	$-33M	$-34M	$-33M	$-33M	$-34M	$-32M	$-37M	$-36M
Low	$-36M	$-34M	$-33M	$-33M	$-34M	$-32M	$-37M	$-36M
High	$-28M	$-34M	$-33M	$-33M	$-34M	$-32M	$-37M	$-36M
EPS Avg	$-0.27	$-0.28	$-0.28	$-0.28	$-0.28	$-0.27	$-0.31	$-0.30
Low	$-0.30	$-0.28	$-0.28	$-0.28	$-0.28	$-0.27	$-0.31	$-0.30
High	$-0.23	$-0.28	$-0.28	$-0.28	$-0.28	$-0.27	$-0.31	$-0.30
Analysts (Rev / EPS)	6 / 6	5 / 4	3 / 2	3 / 2	3 / 2	3 / 2	2 / 3	2 / 3

Earnings Surprises

Recent Analyst Actions

Jun 8, 2026H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Fate Therapeutics (FATE)

Target:$7.00

+253.5%from $1.98

May 19, 2026Jefferies

Fate Therapeutics assumed with a Buy at Jefferies

Target:$4.00

+111.6%from $1.89

Mar 6, 2025Stifel Nicolaus

Fate Therapeutics price target lowered to $3 from $5 at Stifel

Target:$3.00

+188.5%from $1.04

Nov 13, 2024BMO Capital

Fate Therapeutics (FATE) PT Lowered to $5 at BMO Capital

Target:$5.00

+48.4%from $3.37

Aug 14, 2024Stifel Nicolaus

Fate Therapeutics (FATE) PT Lowered to $5 at Stifel

Target:$5.00

+52.9%from $3.27

Jun 17, 2024Piper Sandler

Piper Sandler Upgrades Fate Therapeutics (FATE) to Overweight

Target:$6.00

+66.4%from $3.60

May 16, 2024H.C. Wainwright

Fate Therapeutics (FATE) PT Lowered to $5 at H.C. Wainwright

Target:$5.00

+17.9%from $4.24

May 10, 2024Piper Sandler

Fate Therapeutics (FATE) PT Lowered to $4 at Piper Sandler

Target:$4.00

+3.1%from $3.88

May 10, 2024BMO Capital

Fate Therapeutics (FATE) PT Lowered to $6 at BMO Capital

Target:$6.00

+55.2%from $3.87

May 10, 2024Canaccord Genuity

Fate Therapeutics price target lowered to $9 from $11 at Canaccord

Target:$9.00

+130.8%from $3.90

Jan 9, 2023Goldman Sachs

Goldman Sachs Maintains Sell on Fate Therapeutics, Lowers Price Target to $4

Target:$4.00

-9.1%from $4.40

Jan 6, 2023Morgan Stanley

Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $8

Target:$8.00

+89.6%from $4.22

Jan 6, 2023Piper Sandler

Piper Sandler Downgrades Fate Therapeutics to Neutral, Lowers Price Target to $12

Target:$12.00

+9.1%from $11.00

Jan 6, 2023BMO Capital

BMO Capital Downgrades Fate Therapeutics to Market Perform, Lowers Price Target to $7

Target:$7.00

-36.4%from $11.00

Jan 5, 2023Truist Financial

Fate Therapeutics downgraded to Hold from Buy at Truist

Target:$7.00

-36.4%from $11.00

Dec 15, 2022Goldman Sachs

Fate Therapeutics initiated with a Sell at Goldman Sachs

Target:$10.00

-34.9%from $15.37

Dec 13, 2022Truist Financial

Truist Securities Maintains Buy on Fate Therapeutics, Lowers Price Target to $46

Target:$46.00

+197.6%from $15.46

Dec 13, 2021Oppenheimer

Fate lymphoma update should erase concerns, says Oppenheimer

Target:$135.00

+175.6%from $48.98

Nov 8, 2021Citigroup

Fate Therapeutics upgraded to Buy from Neutral at Citi

Target:$87.00

+43.1%from $60.79

Nov 5, 2021Roth Capital

Fate Therapeutics price target lowered to $60 from $90 at Roth Capital

Target:$60.00

-2.3%from $61.42

Oct 25, 2021Jefferies

Jefferies Stick to Their Buy Rating for Fate Therapeutics

Target:$145.00

+149.3%from $58.16

Aug 20, 2021Piper Sandler

Fate Therapeutics selloff on data a buying opportunity, says Piper Sandler

Target:$113.00

+68.6%from $67.01

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance